Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ideaya Biosciences Inc (IDYA)

Ideaya Biosciences Inc (IDYA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 568,758
  • Shares Outstanding, K 39,306
  • Annual Sales, $ 27,940 K
  • Annual Income, $ -49,760 K
  • 60-Month Beta 0.97
  • Price/Sales 21.45
  • Price/Cash Flow N/A
  • Price/Book 2.13
Trade IDYA with:

Options Overview Details

View History
  • Implied Volatility 100.10% ( +0.96%)
  • Historical Volatility 95.15%
  • IV Percentile 50%
  • IV Rank 25.97%
  • IV High 197.38% on 05/11/22
  • IV Low 65.97% on 01/25/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 5,251
  • Open Int (30-Day) 5,518

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.65
  • Number of Estimates 5
  • High Estimate -0.56
  • Low Estimate -0.79
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -109.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.00 +60.78%
on 09/07/22
15.45 -6.34%
on 09/30/22
+5.09 (+54.26%)
since 09/02/22
3-Month
9.00 +60.78%
on 09/07/22
16.15 -10.40%
on 08/11/22
+0.07 (+0.49%)
since 07/05/22
52-Week
8.14 +77.76%
on 05/09/22
27.25 -46.91%
on 10/06/21
-12.27 (-45.89%)
since 10/05/21

Most Recent Stories

More News
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 8,761,905 shares of its common stock...

IDYA : 14.47 (-5.11%)
IDEAYA Announces Pricing of Public Offering of Common Stock

/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 7,619,048 shares of its common stock...

IDYA : 14.47 (-5.11%)
IDEAYA Announces Proposed Public Offering of Common Stock

/PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80.0 million of shares of its common stock in...

IDYA : 14.47 (-5.11%)
Ideaya (IDYA) Up on Interim Data from Mid-Stage Eye Cancer Study

Ideaya Biosciences (IDYA) reports positive interim results from its mid-stage study, evaluating darovasertib in combination with Pfizer's Xalkori (crizotinib) in metastatic uveal melanoma. Stock up.

PFE : 44.12 (-0.76%)
SESN : 0.4799 (-3.15%)
IDYA : 14.47 (-5.11%)
IMCR : 46.19 (-0.11%)
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line MUM patients...

IDYA : 14.47 (-5.11%)
IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

- Investigator Sponsored Trial sites in Australia include St. Vincent's Hospital, Sydney, Alfred Health, Melbourne, and the Royal Victorian Eye and Ear...

IDYA : 14.47 (-5.11%)
IDEAYA Biosciences to Participate in Investor Conferences in September 2022

/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and...

IDYA : 14.47 (-5.11%)
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate

Preclinical development milestone achieved in connection with ongoing IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC as combo...

IDYA : 14.47 (-5.11%)
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0% and 26.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IDYA : 14.47 (-5.11%)
CDMO : 18.36 (-2.03%)
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Strong balance sheet of ~$324 million cash, cash equivalents and marketable securities as of June 30, 2022 is anticipated to fund planned operations into 2025...

IDYA : 14.47 (-5.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

IDEAYA Biosciences Inc. is an oncology-focused precision medicine company. It focuses on the discovery and development of therapeutics for patients using molecular diagnostics. The company's product pipeline consists of IDE196, MAT2A, PARG, Pol-theta and WRN which are in clinical stage. IDEAYA Biosciences...

See More

Key Turning Points

3rd Resistance Point 15.86
2nd Resistance Point 15.56
1st Resistance Point 15.01
Last Price 14.47
1st Support Level 14.16
2nd Support Level 13.86
3rd Support Level 13.31

See More

52-Week High 27.25
Fibonacci 61.8% 19.95
Fibonacci 50% 17.70
Fibonacci 38.2% 15.44
Last Price 14.47
52-Week Low 8.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar